文献速递心脑血管急症

大规模蛋白质组学预测心血管事件的评估

Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events.
PubMed 文献 · JAMA · 2023-01-01
一句话结论在冰岛人群及他汀治疗的稳定ASCVD患者中,蛋白质风险评分与ASCVD事件显著相关,加入临床风险因素后对区分度的提升有统计学意义但幅度有限。

该研究基于冰岛13540名无主要ASCVD事件史个体的蛋白质组学数据(2000年8月23日至2006年10月26日入组,随访至2018年),开发基于4963种血浆蛋白的蛋白质风险评分,并在4018人测试集中验证:每标准差HR 1.93(95%CI 1.75-2.13)。在临床风险因素模型基础上加入蛋白质风险评分和多基因风险评分,C指数变化0.022(95%CI 0.007-0.038);单独加入蛋白质风险评分C指数变化0.014(95%CI 0.002-0.028)。在二级事件人群(他汀治疗的稳定ASCVD患者,6307名白人,432次事件,中位随访2.2年)中,蛋白质风险评分每标准差HR 1.62(95%CI 1.48-1.79),加入临床模型C指数变化0.026(95%CI 0.011-0.042)。结论认为蛋白质风险评分与ASCVD事件显著相关,但区分度改善幅度有限。

要点

  • 在初级事件人群测试集(4018人,465次事件,中位随访15.8年)中,蛋白质风险评分每标准差HR 1.93(95%CI 1.75-2.13)。
  • 在临床风险因素模型基础上加入蛋白质风险评分和多基因风险评分,C指数变化0.022(95%CI 0.007-0.038);单独加入蛋白质风险评分C指数变化0.014(95%CI 0.002-0.028)。
  • 在二级事件人群白人(6307人,432次事件,中位随访2.2年)中,蛋白质风险评分每标准差HR 1.62(95%CI 1.48-1.79),加入临床模型C指数变化0.026(95%CI 0.011-0.042)。
  • 蛋白质风险评分在二级事件人群中非洲和亚洲 ancestry 个体中与主要不良心血管事件显著相关。
  • 结论:蛋白质风险评分与ASCVD事件显著相关,但加入临床风险因素后区分度改善有统计学意义但幅度有限。

适用人群与场景

  • 初级事件人群:冰岛13540名40-75岁、入组时无主要ASCVD事件史且有蛋白质组学数据的个体(研究期2000年8月23日至2006年10月26日,随访至2018年)。
  • 二级事件人群:来自一项随机双盲降脂临床试验(2013-2016年),为接受他汀治疗的稳定ASCVD患者,有蛋白质组学数据的6791人;其中白人分析集6307人。

研究设计与关键结果

  • 研究类型:初级分析为回顾性研究(初级事件人群),另分析二级事件人群(来自随机双盲降脂临床试验)。
  • 初级事件人群测试集:4018人(59.0%女性),465次事件,中位随访15.8年;蛋白质风险评分每标准差HR 1.93(95%CI 1.75-2.13)。
  • 在临床风险因素模型基础上加入蛋白质风险评分和多基因风险评分,C指数变化0.022(95%CI 0.007-0.038);单独加入蛋白质风险评分,C指数变化0.014(95%CI 0.002-0.028)。
  • 二级事件人群白人:6307人,432次事件,中位随访2.2年;蛋白质风险评分每标准差HR 1.62(95%CI 1.48-1.79);加入临床风险因素模型C指数变化0.026(95%CI 0.011-0.042)。
  • 蛋白质风险评分在二级事件人群中非洲和亚洲 ancestry 个体中与主要不良心血管事件显著相关。

证据类型、等级与局限

  • 证据类型:回顾性研究(初级事件人群)及随机双盲降脂临床试验的二次分析(二级事件人群)。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为,蛋白质风险评分与初级和二级事件人群的ASCVD事件显著相关;加入临床风险因素后,蛋白质风险评分和多基因风险评分均提供有统计学意义但幅度有限的区分度改善。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Whether protein risk scores derived from a single plasma sample could be useful for risk assessment for atherosclerotic cardiovascular disease (ASCVD), in conjunction with clinical risk factors and polygenic risk scores, is uncertain.

OBJECTIVE: To develop protein risk scores for ASCVD risk prediction and compare them to clinical risk factors and polygenic risk scores in primary and secondary event populations.

DESIGN, SETTING, AND PARTICIPANTS: The primary analysis was a retrospective study of primary events among 13 540 individuals in Iceland (aged 40-75 years) with proteomics data and no history of major ASCVD events at recruitment (study duration, August 23, 2000 until October 26, 2006; follow-up through 2018). We also analyzed a secondary event population from a randomized, double-blind lipid-lowering clinical trial (2013-2016), consisting of individuals with stable ASCVD receiving statin therapy and for whom proteomic data were available for 6791 individuals.

EXPOSURES: Protein risk scores (based on 4963 plasma protein levels and developed in a training set in the primary event population); polygenic risk scores for coronary artery disease and stroke; and clinical risk factors that included age, sex, statin use, hypertension treatment, type 2 diabetes, body mass index, and smoking status at the time of plasma sampling.

MAIN OUTCOMES AND MEASURES: Outcomes were composites of myocardial infarction, stroke, and coronary heart disease death or cardiovascular death. Performance was evaluated using Cox survival models and measures of discrimination and reclassification that accounted for the competing risk of non-ASCVD death.

RESULTS: In the primary event population test set (4018 individuals [59.0% women]; 465 events; median follow-up, 15.8 years), the protein risk score had a hazard ratio (HR) of 1.93 per SD (95% CI, 1.75 to 2.13). Addition of protein risk score and polygenic risk scores significantly increased the C index when added to a clinical risk factor model (C index change, 0.022 [95% CI, 0.007 to 0.038]). Addition of the protein risk score alone to a clinical risk factor model also led to a significantly increased C index (difference, 0.014 [95% CI, 0.002 to 0.028]). Among White individuals in the secondary event population (6307 participants; 432 events; median follow-up, 2.2 years), the protein risk score had an HR of 1.62 per SD (95% CI, 1.48 to 1.79) and significantly increased C index when added to a clinical risk factor model (C index change, 0.026 [95% CI, 0.011 to 0.042]). The protein risk score was significantly associated with major adverse cardiovascular events among individuals of African and Asian ancestries in the secondary event population.

CONCLUSIONS AND RELEVANCE: A protein risk score was significantly associated with ASCVD events in primary and secondary event populations. When added to clinical risk factors, the protein risk score and polygenic risk score both provided statistically significant but modest improvement in discrimination.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Helgason H, Eiriksdottir T, Ulfarsson MO, et al. Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events. JAMA. 2023. PMID: 37606673. doi:10.1001/jama.2023.13258

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。